Valuation: NetraMark Holdings Inc.

Market Cap 65.85M 46.66M 41.02M 38.19M 35.07M 4.47B 66.72M 454M 177M 2.21B 175M 171M 7.64B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 65.85M 46.66M 41.02M 38.19M 35.07M 4.47B 66.72M 454M 177M 2.21B 175M 171M 7.64B EV / Sales 2026 *
164x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
03-25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
03-25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
03-25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
1 day-6.76%
Current month+32.47%
1 month+26.45%
3 months-13.70%
6 months-38.10%
Current year-33.15%
1 month 0.4
Extreme 0.4013
0.66
Current year 0.4
Extreme 0.4013
0.89
1 year 0.4
Extreme 0.4013
1.26
3 years 0.11
Extreme 0.114
1.26
5 years 0.1
Extreme 0.1045
1.61
10 years 0.1
Extreme 0.1045
1.61
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-6.76%0.00% - - 51.37M
+1.94%-3.28%-24.26%+17.65% 2,835B
+7.00%-2.46%-17.17%+714.43% 295B
+1.31%+2.65%+174.64%+1,019.73% 114B
+2.03%-4.31%+68.09%+130.09% 87.87B
+4.16%+2.78%-35.34%-13.32% 71.51B
+4.39%-1.23%-33.81%+73.26% 61.25B
+5.31%+2.08%+8.54%+62.80% 43.01B
+1.83%-9.07%-59.25%+27.72% 34.04B
+2.67%+12.48%-31.46%-47.48% 29.97B
Average +0.94%-2.75%+5.55%+220.54% 396.82B
Weighted average by Cap. -0.46%-3.64%-15.46%+110.23%

Financials

2026 *2027 *
Net sales 401K 284K 250K 232K 214K 27.25M 406K 2.76M 1.08M 13.45M 1.07M 1.04M 46.5M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume

Quarterly revenue - Rate of surprise